Senescence Inducer Shikonin ROS-Dependently Suppressed Lung Cancer Progression
Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant transition from lung adenomas to LAC, cellular senescence is regard as a critical physiological barrier against tumor progression. Nevertheless, the...
Saved in:
| Published in | Frontiers in pharmacology Vol. 9; p. 519 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
23.05.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant transition from lung adenomas to LAC, cellular senescence is regard as a critical physiological barrier against tumor progression. Nevertheless, the role of senescence in tumorigenesis is controversial and few senescence inducers are extensively determined. In this study, we used two classical cell lines A549 and H1299 and two NSCLC xenograft models on Balb/c-nude mice to reveal the pro-senescence effects of shikonin and the corresponding underlying mechanism in LAC. Shikonin, a pure compound isolated from the herbal medicine
, remarkably stimulated cellular senescence including increased SAHF formation, enlarged cellular morphology, and induced SA-β-Gal positive staining. Further mechanism study revealed that the pro-senescence effect of shikonin was dependent on the increased intercellular ROS generation, which subsequently triggered DNA damage-p53/p21
axis without activating oncogenes such as Ras and MEK-1. Meanwhile, Kdm2b, an H3K36me2-specific demethylase effectively suppressed ROS generation, was also notably suppressed by shikonin treatment. Moreover, shikonin at 10 mg/kg significantly inhibited tumor weights by 55.84% and 50.98% in A549 and H1299 xenograft model, respectively (
< 0.05) through activating cellular senescence. Our study suggested that shikonin, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment. |
|---|---|
| AbstractList | Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant transition from lung adenomas to LAC, cellular senescence is regard as a critical physiological barrier against tumor progression. Nevertheless, the role of senescence in tumorigenesis is controversial and few senescence inducers are extensively determined. In this study, we used two classical cell lines A549 and H1299 and two NSCLC xenograft models on Balb/c-nude mice to reveal the pro-senescence effects of shikonin and the corresponding underlying mechanism in LAC. Shikonin, a pure compound isolated from the herbal medicine
, remarkably stimulated cellular senescence including increased SAHF formation, enlarged cellular morphology, and induced SA-β-Gal positive staining. Further mechanism study revealed that the pro-senescence effect of shikonin was dependent on the increased intercellular ROS generation, which subsequently triggered DNA damage-p53/p21
axis without activating oncogenes such as Ras and MEK-1. Meanwhile, Kdm2b, an H3K36me2-specific demethylase effectively suppressed ROS generation, was also notably suppressed by shikonin treatment. Moreover, shikonin at 10 mg/kg significantly inhibited tumor weights by 55.84% and 50.98% in A549 and H1299 xenograft model, respectively (
< 0.05) through activating cellular senescence. Our study suggested that shikonin, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment. Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant transition from lung adenomas to LAC, cellular senescence is regard as a critical physiological barrier against tumor progression. Nevertheless, the role of senescence in tumorigenesis is controversial and few senescence inducers are extensively determined. In this study, we used two classical cell lines A549 and H1299 and two NSCLC xenograft models on Balb/c-nude mice to reveal the pro-senescence effects of shikonin and the corresponding underlying mechanism in LAC. Shikonin, a pure compound isolated from the herbal medicine Lithospermum erythrorhizon, remarkably stimulated cellular senescence including increased SAHF formation, enlarged cellular morphology, and induced SA-β-Gal positive staining. Further mechanism study revealed that the pro-senescence effect of shikonin was dependent on the increased intercellular ROS generation, which subsequently triggered DNA damage-p53/p21waf axis without activating oncogenes such as Ras and MEK-1. Meanwhile, Kdm2b, an H3K36me2-specific demethylase effectively suppressed ROS generation, was also notably suppressed by shikonin treatment. Moreover, shikonin at 10 mg/kg significantly inhibited tumor weights by 55.84% and 50.98% in A549 and H1299 xenograft model, respectively (P < 0.05) through activating cellular senescence. Our study suggested that shikonin, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment. Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant transition from lung adenomas to LAC, cellular senescence is regard as a critical physiological barrier against tumor progression. Nevertheless, the role of senescence in tumorigenesis is controversial and few senescence inducers are extensively determined. In this study, we used two classical cell lines A549 and H1299 and two NSCLC xenograft models on Balb/c-nude mice to reveal the pro-senescence effects of shikonin and the corresponding underlying mechanism in LAC. Shikonin, a pure compound isolated from the herbal medicine Lithospermum erythrorhizon, remarkably stimulated cellular senescence including increased SAHF formation, enlarged cellular morphology, and induced SA-β-Gal positive staining. Further mechanism study revealed that the pro-senescence effect of shikonin was dependent on the increased intercellular ROS generation, which subsequently triggered DNA damage-p53/p21waf axis without activating oncogenes such as Ras and MEK-1. Meanwhile, Kdm2b, an H3K36me2-specific demethylase effectively suppressed ROS generation, was also notably suppressed by shikonin treatment. Moreover, shikonin at 10 mg/kg significantly inhibited tumor weights by 55.84% and 50.98% in A549 and H1299 xenograft model, respectively (P < 0.05) through activating cellular senescence. Our study suggested that shikonin, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment.Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant transition from lung adenomas to LAC, cellular senescence is regard as a critical physiological barrier against tumor progression. Nevertheless, the role of senescence in tumorigenesis is controversial and few senescence inducers are extensively determined. In this study, we used two classical cell lines A549 and H1299 and two NSCLC xenograft models on Balb/c-nude mice to reveal the pro-senescence effects of shikonin and the corresponding underlying mechanism in LAC. Shikonin, a pure compound isolated from the herbal medicine Lithospermum erythrorhizon, remarkably stimulated cellular senescence including increased SAHF formation, enlarged cellular morphology, and induced SA-β-Gal positive staining. Further mechanism study revealed that the pro-senescence effect of shikonin was dependent on the increased intercellular ROS generation, which subsequently triggered DNA damage-p53/p21waf axis without activating oncogenes such as Ras and MEK-1. Meanwhile, Kdm2b, an H3K36me2-specific demethylase effectively suppressed ROS generation, was also notably suppressed by shikonin treatment. Moreover, shikonin at 10 mg/kg significantly inhibited tumor weights by 55.84% and 50.98% in A549 and H1299 xenograft model, respectively (P < 0.05) through activating cellular senescence. Our study suggested that shikonin, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment. Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant transition from lung adenomas to LAC, cellular senescence is regard as a critical physiological barrier against tumor progression. Nevertheless, the role of senescence in tumorigenesis is controversial and few senescence inducers are extensively determined. In this study, we used two classical cell lines A549 and H1299 and two NSCLC xenograft models on Balb/c-nude mice to reveal the pro-senescence effects of shikonin and the corresponding underlying mechanism in LAC. Shikonin, a pure compound isolated from the herbal medicine Lithospermum erythrorhizon , remarkably stimulated cellular senescence including increased SAHF formation, enlarged cellular morphology, and induced SA-β-Gal positive staining. Further mechanism study revealed that the pro-senescence effect of shikonin was dependent on the increased intercellular ROS generation, which subsequently triggered DNA damage-p53/p21 waf axis without activating oncogenes such as Ras and MEK-1. Meanwhile, Kdm2b, an H3K36me2-specific demethylase effectively suppressed ROS generation, was also notably suppressed by shikonin treatment. Moreover, shikonin at 10 mg/kg significantly inhibited tumor weights by 55.84% and 50.98% in A549 and H1299 xenograft model, respectively ( P < 0.05) through activating cellular senescence. Our study suggested that shikonin, a ROS-dependent senescence inducer, could serve as a promising agent for further lung cancer treatment. |
| Author | Wang, Wensheng Huang, Qiuju Wang, Haojia Lu, Linlin Ji, Liyan Zheng, Hongming Wang, Ying Qi, Xiaoxiao Zhu, Ting Huang, Suchao Yang, Xia He, Shugui Liu, Zhongqiu |
| AuthorAffiliation | 1 International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine , Guangzhou , China 2 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology , Taipa , Macau |
| AuthorAffiliation_xml | – name: 2 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology , Taipa , Macau – name: 1 International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine , Guangzhou , China |
| Author_xml | – sequence: 1 givenname: Hongming surname: Zheng fullname: Zheng, Hongming – sequence: 2 givenname: Qiuju surname: Huang fullname: Huang, Qiuju – sequence: 3 givenname: Suchao surname: Huang fullname: Huang, Suchao – sequence: 4 givenname: Xia surname: Yang fullname: Yang, Xia – sequence: 5 givenname: Ting surname: Zhu fullname: Zhu, Ting – sequence: 6 givenname: Wensheng surname: Wang fullname: Wang, Wensheng – sequence: 7 givenname: Haojia surname: Wang fullname: Wang, Haojia – sequence: 8 givenname: Shugui surname: He fullname: He, Shugui – sequence: 9 givenname: Liyan surname: Ji fullname: Ji, Liyan – sequence: 10 givenname: Ying surname: Wang fullname: Wang, Ying – sequence: 11 givenname: Xiaoxiao surname: Qi fullname: Qi, Xiaoxiao – sequence: 12 givenname: Zhongqiu surname: Liu fullname: Liu, Zhongqiu – sequence: 13 givenname: Linlin surname: Lu fullname: Lu, Linlin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29875661$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kcFv0zAYxS20iY2xOyeUI5cUO3ac-IKECoNK1YYonC3b-dx6pHawk0n773HaDW1I-GLr8_t-T3rvFTrxwQNCbwheUNqK93bYqbioMGkXGNdEvEDnhHNaipZUJ0_eZ-gypVucDxWCcvYSnVWibWrOyTm63oCHZMAbKFa-mwzEYrNzv4J3vvh-syk_wQC-Az_298VmGoYIKUFXrCe_LZbKz_pvMWznsQv-NTq1qk9w-XBfoJ9Xn38sv5brmy-r5cd1aRivxrKiRnct59YqzBhTouOY2rrtsDaUUBAE8ypLjFVMWGKINqYBqLPa1C3T9AKtjtwuqFs5RLdX8V4G5eRhEOJWqjg604MUJIfQEmaswQwsCM1IYyho1igtNM2sD0fWMOk9dDmLMar-GfT5j3c7uQ13shYNI0xkwLsHQAy_J0ij3Lscad8rD2FKssrt8LrFzez19qnXX5PHQrKAHwUmhpQiWGncqMYcbbZ2vSRYzuXLQ_lyLl8eys-L-J_FR_Z_V_4AkcW0aA |
| CitedBy_id | crossref_primary_10_3389_fphar_2024_1360587 crossref_primary_10_1016_j_ijbiomac_2024_129937 crossref_primary_10_1002_tox_24099 crossref_primary_10_1016_j_phymed_2019_152968 crossref_primary_10_1016_j_phymed_2024_155459 crossref_primary_10_1016_j_phrs_2021_105961 crossref_primary_10_3390_ijms21207580 crossref_primary_10_1002_pmic_201800400 crossref_primary_10_1016_j_jddst_2022_103193 crossref_primary_10_1016_j_semcancer_2024_08_006 crossref_primary_10_3390_cells9020466 crossref_primary_10_1016_j_phrs_2019_104463 crossref_primary_10_1016_j_biopha_2023_116099 crossref_primary_10_1111_bcpt_13648 crossref_primary_10_1016_j_biopha_2022_112966 crossref_primary_10_1016_j_aca_2020_07_079 crossref_primary_10_1016_j_phymed_2020_153189 crossref_primary_10_1186_s12985_023_01964_w crossref_primary_10_15252_emmm_202012146 crossref_primary_10_1128_JVI_00794_21 crossref_primary_10_1042_BSR20181693 crossref_primary_10_3389_fneur_2022_878947 crossref_primary_10_3389_fphar_2021_766165 crossref_primary_10_2174_1389557520666200818212020 crossref_primary_10_3389_fphar_2020_00861 crossref_primary_10_1016_j_fitote_2019_03_005 crossref_primary_10_1016_j_phymed_2021_153805 crossref_primary_10_3390_cells13161345 |
| Cites_doi | 10.1158/0008-5472.CAN-16-0613 10.1007/s12013-014-0083-5 10.1095/biolreprod.110.087569 10.1016/j.molcel.2009.09.021 10.1038/nature10600 10.1111/acel.12518 10.1073/pnas.92.20.9363 10.1002/ptr.1100 10.1038/nrm3823 10.3978/j.issn.2218-676X.2013.07.03 10.1128/MCB.01047-08 10.1371/journal.pbio.0060301 10.1038/nature10189 10.1038/nature12437 10.1016/j.phrs.2016.11.011 10.1073/pnas.91.12.5320 10.1002/ijc.29210 10.18632/oncotarget.12075 10.1101/gad.1256504 10.1158/1535-7163.MCT-13-0137 10.1371/journal.pone.0085155 10.1186/1475-2867-13-9 10.1002/path.4469 10.1016/j.cell.2007.07.003 10.1038/cdd.2014.16 10.1016/j.ccr.2010.05.025 10.1016/j.ejphar.2011.02.043 10.1158/2159-8290.CD-14-1473 10.1371/journal.pcbi.1004246 10.1128/MCB.00688-08 10.1002/jcb.25112 10.4161/cbt.21116 10.1155/2015/620383 10.1083/jcb.200604005 10.1038/nrc3057 10.1083/jcb.201009094 10.1038/ncb2004 10.1200/JCO.2016.34.15_suppl.e12092 10.1016/j.tox.2013.03.015 10.1038/sj.onc.1202632 10.1016/j.tcb.2011.11.006 10.1038/436642a 10.1186/1476-4598-8-3 10.1016/j.ccr.2010.10.002 |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 Zheng, Huang, Huang, Yang, Zhu, Wang, Wang, He, Ji, Wang, Qi, Liu and Lu. 2018 Zheng, Huang, Huang, Yang, Zhu, Wang, Wang, He, Ji, Wang, Qi, Liu and Lu |
| Copyright_xml | – notice: Copyright © 2018 Zheng, Huang, Huang, Yang, Zhu, Wang, Wang, He, Ji, Wang, Qi, Liu and Lu. 2018 Zheng, Huang, Huang, Yang, Zhu, Wang, Wang, He, Ji, Wang, Qi, Liu and Lu |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fphar.2018.00519 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_91981814cfc04efe9b417c3eb47ab9b3 PMC5974149 29875661 10_3389_fphar_2018_00519 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Natural Science Foundation of Guangdong Province grantid: 2015A030312012; 2016A050502052; 2014A020221076 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-23cbd866ffa0444a9d603f58d0bc313e91062cbdcfa49f1c1bcc7ee5a04c584b3 |
| IEDL.DBID | M48 |
| ISSN | 1663-9812 |
| IngestDate | Wed Aug 27 01:21:17 EDT 2025 Thu Aug 21 18:21:07 EDT 2025 Fri Jul 11 10:17:23 EDT 2025 Wed Feb 19 02:42:14 EST 2025 Tue Jul 01 02:25:20 EDT 2025 Thu Apr 24 22:58:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | lung cancer senescence DNA damage ROS shikonin |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-23cbd866ffa0444a9d603f58d0bc313e91062cbdcfa49f1c1bcc7ee5a04c584b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology Edited by: Vincent Kam Wai Wong, Macau University of Science and Technology, Macau These authors have contributed equally to this work. Reviewed by: William Chi-Shing Tai, The Hong Kong Polytechnic University, Hong Kong; W. L. Wendy Hsiao, Macau University of Science and Technology, Macau |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2018.00519 |
| PMID | 29875661 |
| PQID | 2051658073 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_91981814cfc04efe9b417c3eb47ab9b3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5974149 proquest_miscellaneous_2051658073 pubmed_primary_29875661 crossref_citationtrail_10_3389_fphar_2018_00519 crossref_primary_10_3389_fphar_2018_00519 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-23 |
| PublicationDateYYYYMMDD | 2018-05-23 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-23 day: 23 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2018 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Sherr (B37) 2004; 18 Muñoz-Espín (B28) 2014; 15 Dörr (B17) 2013; 501 Tan (B39) 2015; 116 Curado (B12) 2008 Dolan (B16) 2015; 11 Coppé (B11) 2009; 6 Chen (B7) 2002; 16 Chen (B8) 2015; 235 Ogrunc (B30) 2014; 21 Slebos (B38) 1994; 91 Baker (B3) 2011; 479 Shao (B36) 2013; 2 Banumathy (B4) 2009; 29 Yang (B44) 2011; 84 Yeh (B45) 2015; 2015 Han (B21) 2017; 77 Lu (B26) 2011; 658 Funayama (B20) 2006; 175 Fertig (B19) 2016; 7 Li (B23) 2017; 115 Collado (B10) 2005; 436 Ferlay (B18) 2015; 136 Litwiniec (B24) 2013; 13 David (B13) 2012; 13 Lan (B22) 2014; 70 Rodier (B35) 2011; 192 Wang (B42) 1999; 18 DeNicola (B14) 2011; 475 Lleonart (B25) 2009; 8 Petrova (B31) 2016; 15 Mcdermott (B27) 2016 Campaner (B6) 2010; 12 Collado (B9) 2007; 130 Venturelli (B40) 2013; 12 Adams (B2) 2009; 36 Puyol (B33) 2010; 18 Polytarchou (B32) 2008; 28 Nardella (B29) 2011; 11 Xie (B43) 2015; 5 Acosta (B1) 2012; 22 Wang (B41) 2013; 308 Dimri (B15) 1995; 92 Burchett (B5) 2014; 9 Rakhra (B34) 2010; 18 24972691 - Cell Biochem Biophys. 2014 Nov;70(2):1459-67 22245068 - Trends Cell Biol. 2012 Apr;22(4):211-9 25737737 - Evid Based Complement Alternat Med. 2015;2015:620383 19029251 - Mol Cell Biol. 2009 Feb;29(3):758-70 8202487 - Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5320-4 19818705 - Mol Cell. 2009 Oct 9;36(1):2-14 7568133 - Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 12164262 - Phytother Res. 2002 May;16(3):199-209 25673642 - Cancer Discov. 2015 Apr;5(4):410-23 21392503 - Eur J Pharmacol. 2011 May 11;658(2-3):242-7 24605290 - Transl Cancer Res. 2013 Oct;2(5):397-411 27628712 - Aging Cell. 2016 Sep 14;:null 21321098 - J Cell Biol. 2011 Feb 21;192(4):547-56 19053174 - PLoS Biol. 2008 Dec 2;6(12):2853-68 25649549 - J Cell Biochem. 2015 Aug;116(8):1583-94 18838535 - Mol Cell Biol. 2008 Dec;28(24):7451-64 24583638 - Cell Death Differ. 2014 Jun;21(6):998-1012 27650546 - Oncotarget. 2016 Nov 8;7(45):73845-73864 17662938 - Cell. 2007 Jul 27;130(2):223-33 22048312 - Nature. 2011 Nov 02;479(7372):232-6 21035406 - Cancer Cell. 2010 Nov 16;18(5):485-98 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86 21701512 - Nat Rev Cancer. 2011 Jun 24;11(7):503-11 25345926 - J Pathol. 2015 Feb;235(3):397-407 22825329 - Cancer Biol Ther. 2012 Sep;13(11):992-1000 24409321 - PLoS One. 2014 Jan 07;9(1):e85155 26020242 - PLoS Comput Biol. 2015 May 28;11(5):e1004246 17158953 - J Cell Biol. 2006 Dec 18;175(6):869-80 19133111 - Mol Cancer. 2009 Jan 08;8:3 16079833 - Nature. 2005 Aug 4;436(7051):642 23924947 - Mol Cancer Ther. 2013 Oct;12(10):2226-36 20609353 - Cancer Cell. 2010 Jul 13;18(1):63-73 20010815 - Nat Cell Biol. 2010 Jan;12(1):54-9; sup pp 1-14 21248284 - Biol Reprod. 2011 Jun;84(6):1182-9 24954210 - Nat Rev Mol Cell Biol. 2014 Jul;15(7):482-96 21734707 - Nature. 2011 Jul 06;475(7354):106-9 23562787 - Toxicology. 2013 Jun 7;308:104-12 23383739 - Cancer Cell Int. 2013 Feb 05;13(1):9 27793846 - Cancer Res. 2017 Jan 15;77(2):343-354 15545627 - Genes Dev. 2004 Nov 15;18(22):2699-711 23945590 - Nature. 2013 Sep 19;501(7467):421-5 27864022 - Pharmacol Res. 2017 Jan;115:45-55 10353608 - Oncogene. 1999 Apr 22;18(16):2643-9 |
| References_xml | – volume: 77 start-page: 343 year: 2017 ident: B21 article-title: Molecular chaperone HSP90 is necessary to prevent cellular senescence via lysosomal degradation of p14ARF. publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-0613 – volume: 70 start-page: 1459 year: 2014 ident: B22 article-title: Mechanisms behind the inhibition of lung adenocarcinoma cell by shikonin. publication-title: Cell Biochem. Biophys. doi: 10.1007/s12013-014-0083-5 – volume: 84 start-page: 1182 year: 2011 ident: B44 article-title: Peroxiredoxin 2 inhibits granulosa cell apoptosis during follicle atresia through the NFKB pathway in mice. publication-title: Biol. Reprod. doi: 10.1095/biolreprod.110.087569 – volume: 36 start-page: 2 year: 2009 ident: B2 article-title: Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. publication-title: Mol. Cell doi: 10.1016/j.molcel.2009.09.021 – volume: 479 start-page: 232 year: 2011 ident: B3 article-title: Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. publication-title: J. Agric. Biotechnol. doi: 10.1038/nature10600 – volume: 15 start-page: 999 year: 2016 ident: B31 article-title: Small molecule compounds that induce cellular senescence. publication-title: Aging Cell doi: 10.1111/acel.12518 – volume: 92 start-page: 9363 year: 1995 ident: B15 article-title: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.92.20.9363 – volume: 16 start-page: 199 year: 2002 ident: B7 article-title: Cellular pharmacology studies of shikonin derivatives. publication-title: Phytother. Res. doi: 10.1002/ptr.1100 – volume: 15 start-page: 482 year: 2014 ident: B28 article-title: Cellular senescence: from physiology to pathology. publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm3823 – volume: 2 start-page: 397 year: 2013 ident: B36 article-title: Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury. publication-title: Transl. Cancer Res. doi: 10.3978/j.issn.2218-676X.2013.07.03 – volume: 29 start-page: 758 year: 2009 ident: B4 article-title: Human UBN1 is an ortholog of yeast Hpc2p and has an essential role in the HIRA/ASF1a chromatin-remodeling pathway in senescent cells. publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.01047-08 – volume: 6 start-page: 2853 year: 2009 ident: B11 article-title: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. publication-title: PLoS Biol. doi: 10.1371/journal.pbio.0060301 – volume: 475 start-page: 106 year: 2011 ident: B14 article-title: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. publication-title: Nature doi: 10.1038/nature10189 – volume: 501 start-page: 421 year: 2013 ident: B17 article-title: Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. publication-title: Nature doi: 10.1038/nature12437 – volume: 115 start-page: 45 year: 2017 ident: B23 article-title: Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway. publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2016.11.011 – volume: 91 start-page: 5320 year: 1994 ident: B38 article-title: p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.91.12.5320 – volume: 136 start-page: E359 year: 2015 ident: B18 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. publication-title: Int. J. Cancer doi: 10.1002/ijc.29210 – volume: 7 start-page: 73845 year: 2016 ident: B19 article-title: CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. publication-title: Oncotarget doi: 10.18632/oncotarget.12075 – volume: 18 start-page: 2699 year: 2004 ident: B37 article-title: Living with or without cyclins and cyclin-dependent kinases. publication-title: Genes Dev. doi: 10.1101/gad.1256504 – volume: 12 start-page: 2226 year: 2013 ident: B40 article-title: Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2’-deoxycytidine in solid tumor cells. publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-13-0137 – volume: 9 year: 2014 ident: B5 article-title: Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. publication-title: PLoS One doi: 10.1371/journal.pone.0085155 – volume: 13 year: 2013 ident: B24 article-title: Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: does the response involve senescence? The possible role of vimentin. publication-title: Cancer Cell Int. doi: 10.1186/1475-2867-13-9 – volume: 235 start-page: 397 year: 2015 ident: B8 article-title: HOPX is methylated and exerts tumour-suppressive function through Ras-induced senescence in human lung cancer. publication-title: J. Pathol. doi: 10.1002/path.4469 – volume: 130 start-page: 223 year: 2007 ident: B9 article-title: Cellular senescence in cancer and aging. publication-title: Cell doi: 10.1016/j.cell.2007.07.003 – volume: 21 start-page: 998 year: 2014 ident: B30 article-title: Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. publication-title: Cell Death Differ. doi: 10.1038/cdd.2014.16 – volume: 18 start-page: 63 year: 2010 ident: B33 article-title: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.05.025 – volume: 658 start-page: 242 year: 2011 ident: B26 article-title: Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2011.02.043 – volume: 5 start-page: 410 year: 2015 ident: B43 article-title: Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-14-1473 – volume: 11 year: 2015 ident: B16 article-title: Integrated stochastic model of DNA damage repair by non-homologous end joining and p53/p21-mediated early senescence signalling. publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.1004246 – volume: 28 start-page: 7451 year: 2008 ident: B32 article-title: The JmjC domain histone demethylase Ndy1 regulates redox homeostasis and protects cells from oxidative stress. publication-title: Mol. Cell. Biol. doi: 10.1128/MCB.00688-08 – volume: 116 start-page: 1583 year: 2015 ident: B39 article-title: PTEN/Akt-p27(kip1) signaling promote the BM-MSCs senescence and apoptosis in SLE patients. publication-title: J. Cell. Biochem. doi: 10.1002/jcb.25112 – volume: 13 start-page: 992 year: 2012 ident: B13 article-title: Regulation of oncogene-induced cell cycle exit and senescence by chromatin modifiers. publication-title: Cancer Biol. Ther. doi: 10.4161/cbt.21116 – volume: 2015 year: 2015 ident: B45 article-title: Shikonin induces apoptosis, necrosis, and premature senescence of human A549 lung cancer cells through upregulation of p53 expression. publication-title: Evid. Based Complement. Alternat. Med. doi: 10.1155/2015/620383 – volume: 175 start-page: 869 year: 2006 ident: B20 article-title: Loss of linker histone H1 in cellular senescence. publication-title: J. Cell Biol. doi: 10.1083/jcb.200604005 – volume: 11 start-page: 503 year: 2011 ident: B29 article-title: Pro-senescence therapy for cancer treatment. publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3057 – volume: 192 start-page: 547 year: 2011 ident: B35 article-title: Four faces of cellular senescence. publication-title: J. Cell Biol. doi: 10.1083/jcb.201009094 – volume: 12 start-page: 54 year: 2010 ident: B6 article-title: Cdk2 suppresses cellular senescence induced by the c-myc oncogene. publication-title: Nat. Cell Biol. doi: 10.1038/ncb2004 – year: 2016 ident: B27 article-title: Irreversible panHER tyrosine kinase inhibitors (TKIs) to induce irreversible senescence in HER2 positive breast cancer cells. publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.e12092 – volume: 308 start-page: 104 year: 2013 ident: B41 article-title: Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin beta1 expression and the ERK1/2 signaling pathway. publication-title: Toxicology doi: 10.1016/j.tox.2013.03.015 – volume: 18 start-page: 2643 year: 1999 ident: B42 article-title: Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. publication-title: Oncogene doi: 10.1038/sj.onc.1202632 – volume: 22 start-page: 211 year: 2012 ident: B1 article-title: Senescence: a new weapon for cancer therapy. publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2011.11.006 – year: 2008 ident: B12 publication-title: Cancer Incidence in Five Continents – volume: 436 year: 2005 ident: B10 article-title: Tumour biology: senescence in premalignant tumours. publication-title: Nature doi: 10.1038/436642a – volume: 8 year: 2009 ident: B25 article-title: Senescence induction; a possible cancer therapy. publication-title: Mol. Cancer doi: 10.1186/1476-4598-8-3 – volume: 18 start-page: 485 year: 2010 ident: B34 article-title: CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. publication-title: Cancer Cell doi: 10.1016/j.ccr.2010.10.002 – reference: 24972691 - Cell Biochem Biophys. 2014 Nov;70(2):1459-67 – reference: 12164262 - Phytother Res. 2002 May;16(3):199-209 – reference: 16079833 - Nature. 2005 Aug 4;436(7051):642 – reference: 17662938 - Cell. 2007 Jul 27;130(2):223-33 – reference: 21035406 - Cancer Cell. 2010 Nov 16;18(5):485-98 – reference: 25649549 - J Cell Biochem. 2015 Aug;116(8):1583-94 – reference: 27650546 - Oncotarget. 2016 Nov 8;7(45):73845-73864 – reference: 22245068 - Trends Cell Biol. 2012 Apr;22(4):211-9 – reference: 21248284 - Biol Reprod. 2011 Jun;84(6):1182-9 – reference: 25737737 - Evid Based Complement Alternat Med. 2015;2015:620383 – reference: 21701512 - Nat Rev Cancer. 2011 Jun 24;11(7):503-11 – reference: 19053174 - PLoS Biol. 2008 Dec 2;6(12):2853-68 – reference: 20609353 - Cancer Cell. 2010 Jul 13;18(1):63-73 – reference: 26020242 - PLoS Comput Biol. 2015 May 28;11(5):e1004246 – reference: 21321098 - J Cell Biol. 2011 Feb 21;192(4):547-56 – reference: 23945590 - Nature. 2013 Sep 19;501(7467):421-5 – reference: 19133111 - Mol Cancer. 2009 Jan 08;8:3 – reference: 7568133 - Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 – reference: 27864022 - Pharmacol Res. 2017 Jan;115:45-55 – reference: 25345926 - J Pathol. 2015 Feb;235(3):397-407 – reference: 23383739 - Cancer Cell Int. 2013 Feb 05;13(1):9 – reference: 24583638 - Cell Death Differ. 2014 Jun;21(6):998-1012 – reference: 24409321 - PLoS One. 2014 Jan 07;9(1):e85155 – reference: 22048312 - Nature. 2011 Nov 02;479(7372):232-6 – reference: 21734707 - Nature. 2011 Jul 06;475(7354):106-9 – reference: 24605290 - Transl Cancer Res. 2013 Oct;2(5):397-411 – reference: 27793846 - Cancer Res. 2017 Jan 15;77(2):343-354 – reference: 23562787 - Toxicology. 2013 Jun 7;308:104-12 – reference: 8202487 - Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5320-4 – reference: 19029251 - Mol Cell Biol. 2009 Feb;29(3):758-70 – reference: 23924947 - Mol Cancer Ther. 2013 Oct;12(10):2226-36 – reference: 24954210 - Nat Rev Mol Cell Biol. 2014 Jul;15(7):482-96 – reference: 22825329 - Cancer Biol Ther. 2012 Sep;13(11):992-1000 – reference: 10353608 - Oncogene. 1999 Apr 22;18(16):2643-9 – reference: 19818705 - Mol Cell. 2009 Oct 9;36(1):2-14 – reference: 25673642 - Cancer Discov. 2015 Apr;5(4):410-23 – reference: 17158953 - J Cell Biol. 2006 Dec 18;175(6):869-80 – reference: 20010815 - Nat Cell Biol. 2010 Jan;12(1):54-9; sup pp 1-14 – reference: 25220842 - Int J Cancer. 2015 Mar 1;136(5):E359-86 – reference: 15545627 - Genes Dev. 2004 Nov 15;18(22):2699-711 – reference: 27628712 - Aging Cell. 2016 Sep 14;:null – reference: 21392503 - Eur J Pharmacol. 2011 May 11;658(2-3):242-7 – reference: 18838535 - Mol Cell Biol. 2008 Dec;28(24):7451-64 |
| SSID | ssj0000399364 |
| Score | 2.3281145 |
| Snippet | Lung adenocarcinoma (LAC), predominant subclassfication of lung cancer, leads high incidence and mortality annually worldwide. During the premalignant... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 519 |
| SubjectTerms | DNA damage lung cancer Pharmacology ROS senescence shikonin |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS-QwEA_i072IeqfW-yCCCIJl2yZNm8c770TEj8VV8K0k04RdlCrr-rD_vTNpXXdFvBffSps2ITOZmV8z-Q1ju6ZQvqwzHZcmk7EUYGJjdRJrJ5zSaQ6ZogPOZ-fq-Fqe3OQ3c6W-KCespQduJ66nERWjF5LgIZHOO21lWoBwVhb4URt4PtHnzYGpYIPJ7yrZ7ksiCtM9_zA0xP-ZUu5kTsQ6c34o0PW_F2O-TZWc8z1Hq2ylCxr573awa2zJNetsr9-yTk8P-NXrIarHA77H-6981NOv7HxA9gxoCXOq1AFuzAfD0S39iOWXF4P4b1cId3I35VTlM_CJ1_wU7QA_JK0Y8z6lcbUUHt_Y9dG_q8PjuCujEINU2STOBNi6VMp7Q-RwRtcqET4v68SCSIXDgEFl2AS8kdqnkFqAwrkcWwOGJ1ZssOXmvnFbjCfG59ZbKGuNwLBUdJ24BISViVfCR6z3MqkVdBzjVOrirkKsQWKoghgqEkMVxBCx_dkbDy2_xgdt_5CcZu2IGTvcQH2pOn2p_qcvEdt5kXKFK4m2R0zj7p8esaM8xXgMbV7ENlupz7rKNOI6DGUiVizow8JYFp80o2Fg6ybEhjB0-zMG_519oemg7IVM_GDLk_GT-4lB0cT-Cvr_DMmUDqE priority: 102 providerName: Directory of Open Access Journals |
| Title | Senescence Inducer Shikonin ROS-Dependently Suppressed Lung Cancer Progression |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29875661 https://www.proquest.com/docview/2051658073 https://pubmed.ncbi.nlm.nih.gov/PMC5974149 https://doaj.org/article/91981814cfc04efe9b417c3eb47ab9b3 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfQeOEF8U1gTEZCk5AWlsSOEz8gBINpQmxUdJX2FtkXe52o0i3tJPrfc-ekLUUVD7xFyVmOfHe-3_njd4y9MYXyZZ3puDSZjKUAExurk1g74ZROc8gUXXA-PVMnI_n1Ir9YX4_uB3C2NbWjelKjdvLu183iAzr8e8o4Md4e-uuxIWrPlI5F5sQBehfjUkFuetqD_TAvUyxWstur3NqQmIExB0eEk26EqcDmvw2C_n2S8o_QdPyA3e8xJf_YGcFDdsc1j9j-oCOlXhzw8_Udq9kB3-eDNV314jE7G9J0B-ThnAp5gGv5cHz1k9Zp-Y_vw_hzXyd3PllwKgIa6MZr_g2nCX5ERtPyAZ3y6hg-nrDR8Zfzo5O4r7IQg1TZPM4E2LpUyntD3HFG1yoRPi_rxIJIhUM8oTIUAW-k9imkFqBwLkdpQPRixVO200wb95zxxPjcegtlrTFvLBU9Jy4BYWXilfARO1wOagU9BTlVwphUmIqQRqqgkYo0UgWNROztqsV1R7_xD9lPpKeVHBFnhxfT9rLq_bDSqUaIkkrwkEjnnbZoKSCclQXaqBURe73UcoWORrsnpnHT2xl2lKcI13BKjNizTuurrpZWE7Fiwx42_mXzS3M1DmTelNBhlvriv1u-ZPdoDOhEQyZ22c68vXWvECjN7V5YYNgLXvAbNhMXlA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Senescence+Inducer+Shikonin+ROS-Dependently+Suppressed+Lung+Cancer+Progression&rft.jtitle=Frontiers+in+pharmacology&rft.au=Zheng%2C+Hongming&rft.au=Huang%2C+Qiuju&rft.au=Huang%2C+Suchao&rft.au=Yang%2C+Xia&rft.date=2018-05-23&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=9&rft_id=info:doi/10.3389%2Ffphar.2018.00519&rft_id=info%3Apmid%2F29875661&rft.externalDocID=PMC5974149 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |